Stabilization of AHF using heparin

Claim 3

The method of claim 1 in which the plasma fraction is a cryoprecipitate concentrate of AHF which is further fractionated with both polyethylene glycol and glycine.

Claim 4

The method of claim 2 in which the polyethylene glycol has an average molecular weight of about 4000.

Claim 5

The method of claim 2 in which the cryoprecipitate concentrate is precipitated with from about 3% to about 4% polyethylene glycol, the resulting supernant is precipitated with about 10% polyethylene glycol, and the resulting supernate is then fractionated with glycine.

Claim 6

The method of claim 4 in which the polyethylene glycol has an average molecular weight of about 4000.

Claim 7

The method of claim 4 in which the glycine has a molarity of about 1.8.

Claim 8

The method of claim 4 in which the polyethylene glycol has an average molecular weight of about 4000 and the glycine has a molarity of about 1.8. .Iadd.8. The method of claim 1 wherein citrate in addition to heparin is admixed with said concentrate of AHF. .Iaddend..Iadd. 9. The method of claim 1 wherein the heparin admixed with said concentrate of AHF is a citrate solution of heparin. .Iaddend. .Iadd. 10. The method of claim 1 further including the steps of fractionating the concentrate of AHF with which the heparin is admixed to increase the concentration of AHF, and admixing additional heparin with the further fractionated concentrate of AHF..Iaddend..Iadd. 11. The method of claim 10 wherein citrate in addition to heparin is admixed with said further fractionated concentrate of AHF. .Iaddend..Iadd. 12. The method of claim 11 wherein the additional heparin admixed with said further fractionated concentrate of AHF is a citrate solution of heparin. .Iaddend. .Iadd. 13. The method of improving the yield of AHF comprising the addition of heparin and a citrate to a concentrate of AHF obtained from plasma or a plasma fraction by cryoprecipitation, said heparin being added in an amount of about 0.01 to about 10 units per ml. of solution of said concentrate of AHF. .Iaddend..Iadd. 14. The method of claim 13 wherein about 1 to 10 units of heparin is added per ml. of solution of said concentrate of AHF. .Iaddend..Iadd. 15. The method of claim 13 wherein the heparin containing concentrate of AHF is further fractionated to increase the concentration of the AHF, and additional heparin and citrate are added to the further fractionated concentrate of AHF. .Iaddend. .Iadd. 16. The method of improving the yield of AHF obtained from an AHF-rich cryoprecipitate comprising forming a solution of said cryoprecipitate and providing in said solution from an external source heparin and citrate, said heparin being added in an amount of about 0.01 to about 10 units per ml. of solution of said cryoprecipitate. .Iaddend..Iadd. 17. The method of claim 16 wherein said solution is provided from an external source with about 1 to 10 units of heparin per ml. .Iaddend..Iadd. 18. The method of improving the yield of an AHF concentrate prepared from plasma and plasma fractions comprising: separating an AHF-rich cryoprecipitate from blood plasma or a blood plasma fraction; adding heparin and citrate to the cryoprecipitate, said heparin being added in an amount of about 0.01 to about 10 units per ml. of solution of said cryoprecipitate; fractionating the heparin containing AHF cryoprecipitate with polyethylene glycol to further concentrate the AHF; and adding heparin and citrate to the further concentrated AHF, said heparin being added in an amount of about 0.01 to about 10 units per ml. of solution of said further concentrated AHF. .Iaddend..Iadd. 19. The method of claim 18 wherein the heparin-treated, further concentrated AHF is fractionated with glycine. .Iaddend. .Iadd. 20. The method of improving the yield of an AHF concentrate obtained from plasma by cryoprecipitation, comprising forming a solution of said concentrate of AHF and providing in said solution about 0.01 to about 10 units of externally added heparin per ml. of solution. .Iaddend..Iadd. 21. The method of claim 20 further including the step of providing in said solution a citrate. .Iaddend.